A recent trend observed in the tissue diagnostics industry is increasing usage of immunohistochemistry products as companion diagnostics devices. Increasing prevalence of cancer has fuelled the demand of better diagnostic techniques, which could detect cancer in the earliest stage. According to the WHO, in 2012, there were 14 million new cancer cases and 8.2 million cancer related deaths worldwide.
The global tissue diagnostics market is categorized on the basis of product type, technology, application, and end-user. Based on product type, the tissue diagnostics market can be categorized as instruments and consumables. On the basis of technology, the tissue diagnostics market is categorized as digital pathology and workflow management, in situ hybridization, immunohistochemistry, and special staining. The immunohistochemistry segment leads the global tissue diagnostics market in terms of market size.
Request for report sample at: https://www.psmarketresearch.com/market-analysis/tissue-diagnostics-market/report-sample
Some of the factors driving the growth of the global tissue diagnostics market are increasing prevalence of cancer, increasing investment in tissue diagnostics by pharmaceutical companies, rising awareness for cancer, rapidly aging population, technological advancements in tissue diagnostics procedures, and increasing healthcare expenditure. In addition, tissue diagnostic procedures enable medical professionals to detect cancer in early stage; hence, fueling the growth of the market. However, high cost of tissue diagnostics instruments and stringent regulatory requirements are some of the factors restraining the growth of the global tissue diagnostics market to some extent.
Some of the major players operating in the global tissue diagnostics market are F. Hoffmann-La Roche AG., Sigma Aldrich Corporation, Abbott, Biogenex Laboratories, BioSB, Cell Signalling Technology Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, GE Healthcare, and Siemens Healthcare.
留言列表
